NCT07657949 SPSIP Block for Pain Control After Breast Reduction Surgery
| NCT ID | NCT07657949 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cumhuriyet University Hospital |
| Condition | Postoperative Pain Breast Reduction |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-08-24 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-08-24 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn whether an ultrasound-guided serratus posterior superior intercostal plane block (SPSIP block) can lower the need for opioid pain medicine after breast reduction surgery. The main question it aims to answer is: Does adding an SPSIP block to standard anesthesia and pain treatment lower opioid use during the first 24 hours after surgery? Researchers will compare participants who receive standard anesthesia and pain treatment with participants who receive standard anesthesia and pain treatment plus an SPSIP block. Participants will: * Have planned bilateral breast reduction surgery under general anesthesia * Be randomly assigned to the SPSIP block group or the control group * Receive standard local anesthetic infiltration during surgery and standard pain treatment after surgery * Have their pain score and pain medicine use recorded during the first 24 hours after surgery * Be followed for safety and complications for 30 days after surgery
Eligibility Criteria
Inclusion Criteria: * Female participants aged 18 to 65 years * Scheduled for elective bilateral reduction mammaplasty * Planned surgery under general anesthesia * American Society of Anesthesiologists physical status class I to III * Planned postoperative clinical follow-up for the first 24 hours after surgery * Able to understand and report pain using the 0 to 10 Numeric Rating Scale * Able to provide written informed consent for study participation Exclusion Criteria: * Known allergy or hypersensitivity to local anesthetic drugs * Contraindication to regional anesthesia or fascial plane block * Coagulopathy or clinically significant bleeding disorder * Use of anticoagulant or antiplatelet medication that prevents safe block application * Infection at the planned block injection site * Chronic opioid use, chronic pain syndrome, or regular analgesic use that may affect postoperative pain assessment * Revision breast surgery * Planned major additional surgical procedure other than reduction mammaplasty * Pregnancy or lactation * Unable to reliably report pain scores
Contact & Investigator
Handan Derebaşınlıoğlu, Associate Professor
STUDY DIRECTOR
Cumhuriyet University
Frequently Asked Questions
Who can join the NCT07657949 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying Postoperative Pain Breast Reduction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07657949 currently recruiting?
Yes, NCT07657949 is actively recruiting participants. Contact the research team at mucetr@gmail.com for enrollment information.
Where is the NCT07657949 trial being conducted?
This trial is being conducted at Sivas, Turkey (Türkiye).
Who is sponsoring the NCT07657949 clinical trial?
NCT07657949 is sponsored by Cumhuriyet University Hospital. The principal investigator is Handan Derebaşınlıoğlu, Associate Professor at Cumhuriyet University. The trial plans to enroll 80 participants.